Vanguard Capital Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Vanguard Capital Management's SMMT Position: Q3 2026 in Review
Vanguard Capital Management increased its Summit Therapeutics (SMMT) stake by 26% in Q3 2026, buying an estimated $22.4M and bringing the position to 7,230,441 shares worth $122M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.
Vanguard Capital Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Vanguard Capital Management held 7,230,441 shares of Summit Therapeutics worth $122M as of Q3 2026.
- Vanguard Capital Management bought 1,495,957 Summit Therapeutics shares in Q3 2026, an estimated $22.4M.
- Summit Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1405 holding.
- Vanguard Capital Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.